Subcutaneous injectable TLD might be dosed once a month
Researchers at the University of Washington in Seattle say they have cracked the challenge of creating a long-acting injectable form of the world’s most commonly prescribed antiretroviral combination, tenofovir disoproxil fumarate, lamivudine and dolutegravir, often known as TLD.
But the drawback is that the long-acting formulation only lasts for one month.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
WAD 2023 | Stigma-Free: EATG calls for stigma-free integrated services – Video
-
Innovative HIV prevention product for women that promotes choice – dapivirine vaginal ring – gains momentum across Africa
-
Progress continues to accelerate access to cabotegravir LA for PrEP in low and middle-income countries
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.